PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. Electronic address: a.lasagna@smatteo.pv.it.\', \'Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.\', \'Molecular Virology Unit, Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.\', \'Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.\', \'Microbiology Unit, Hospital Guglielmo da Saliceto, Piacenza, Italy.\', \'Service of Clinical Epidemiology & Biometry, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.\', \'Oncology Unit, Hospital Guglielmo da Saliceto, Piacenza, Italy.\', \'Molecular Virology Unit, Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.\', \'Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.\']
?:citedBy
  • -1
?:creator
?:doi
  • S2059-7029(21)00234-910.1016/j.esmoop.2021.100272
?:doi
?:hasPublicationType
?:journal
  • ESMO open
is ?:pmid of
?:pmid
?:pmid
  • 34543863
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all